Sep 26, 2022
Immutep to Participate in Two Upcoming Investor Conferences
Sep 22, 2022
Immutep Receives A$2.7 million R&D Tax Incentive from French Government
Sep 13, 2022
Immutep Clinical Development Update for its First-in-Class LAG-3 Antigen Presenting Cell Activator Candidate Eftilagimod Alpha
Sep 12, 2022
Immutep Appoints LAG-3 Pioneer, Dr Frédéric Triebel to Board
Sep 05, 2022
Immutep Announces Investigator-Initiated Phase II Trial Evaluating LAG-3 Candidate Eftilagimod Alpha (Efti) in Soft Tissue Sarcoma
Aug 29, 2022
Immutep Granted Japanese Patent for Eftilagimod Alpha, a Soluble Lag-3 Protein, in Combination with a PD-1 Pathway Inhibitor
Jul 31, 2022
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd line PD-X Refractory NSCLC
Jul 28, 2022
Immutep Quarterly Activities Report
Jul 05, 2022
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3
Jun 26, 2022
Immutep to Announce New TACTI-002 Data at the 2022 World Conference on Lung Cancer
Jun 03, 2022
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers
Jun 01, 2022
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022
